Free Trial
NYSE:STVN

Stevanato Group (STVN) Stock Price, News & Analysis

Stevanato Group logo
€20.56 -0.78 (-3.66%)
(As of 12/20/2024 08:57 PM ET)

About Stevanato Group Stock (NYSE:STVN)

Key Stats

Today's Range
€20.21
€21.50
50-Day Range
€17.27
€23.67
52-Week Range
€16.56
€34.73
Volume
614,800 shs
Average Volume
503,307 shs
Market Capitalization
$6.08 billion
P/E Ratio
43.74
Dividend Yield
0.29%
Price Target
N/A
Consensus Rating
Moderate Buy

Company Overview

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Stevanato Group Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
31st Percentile Overall Score

STVN MarketRank™: 

Stevanato Group scored higher than 31% of companies evaluated by MarketBeat, and ranked 787th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Stevanato Group are expected to grow by 18.00% in the coming year, from €0.50 to €0.59 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Stevanato Group is 43.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 115.29.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Stevanato Group is 43.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.08.

  • Price to Earnings Growth Ratio

    Stevanato Group has a PEG Ratio of 10.49. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Stevanato Group has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.50% of the float of Stevanato Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Stevanato Group has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Stevanato Group has recently increased by 1.37%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Stevanato Group has a dividend yield of 0.25%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Stevanato Group does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Stevanato Group is 12.77%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Stevanato Group will have a dividend payout ratio of 10.17% next year. This indicates that Stevanato Group will be able to sustain or increase its dividend.

  • Read more about Stevanato Group's dividend.
  • Percentage of Shares Shorted

    7.50% of the float of Stevanato Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Stevanato Group has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Stevanato Group has recently increased by 1.37%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Stevanato Group has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Stevanato Group this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for STVN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
Receive STVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stevanato Group and its competitors with MarketBeat's FREE daily newsletter.

STVN Stock News Headlines

Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
Stevanato Group (NYSE:STVN) Stock Price Up 4.9% on Analyst Upgrade
See More Headlines

STVN Stock Analysis - Frequently Asked Questions

Stevanato Group's stock was trading at €27.29 at the start of the year. Since then, STVN shares have decreased by 24.7% and is now trading at €20.56.
View the best growth stocks for 2024 here
.

Stevanato Group S.p.A. (NYSE:STVN) issued its quarterly earnings data on Tuesday, November, 5th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.13 by $0.01. The company's quarterly revenue was up 2.4% compared to the same quarter last year.

Stevanato Group (STVN) raised $720 million in an initial public offering on Friday, July 16th 2021. The company issued 32,000,000 shares at $21.00-$24.00 per share.

Stevanato Group's top institutional investors include Conestoga Capital Advisors LLC, Thrivent Financial for Lutherans, Wellington Management Group LLP and Bamco Inc. NY.

Shares of STVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stevanato Group investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Fortinet (FTNT), Antero Resources (AR), CrowdStrike (CRWD), Walt Disney (DIS) and Onsemi (ON).

Company Calendar

Last Earnings
11/05/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Fax
N/A
Employees
5,635
Year Founded
N/A

Profitability

Net Income
$157.62 million
Pretax Margin
14.11%

Debt

Sales & Book Value

Annual Sales
$1.09 billion
Cash Flow
€0.75 per share
Book Value
€4.15 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.08 billion
Optionable
Optionable
Beta
0.59
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NYSE:STVN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners